Want to see ELAB full AI Analyst Report?
ELAB Stock Chart & Stats
$1.55
-$0.19(-8.12%)
At close: 4:00 PM EST
$1.55
-$0.19(-8.12%)
Day’s Range― - ―
52-Week Range$1.02 - $309.12
Previous CloseN/A
Volume180.10K
Average Volume (3M)89.87K
Market Cap
$4.82M
Enterprise Value-$3.63M
Total Cash (Recent Filing)$15.09M
Total Debt (Recent Filing)$7.96M
Price to Earnings (P/E)―
Beta2.63
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,543,751
10 Day Avg. Volume35,159
30 Day Avg. Volume89,868
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)4.90
P/FCF Ratio-0.45
Enterprise Value/Market Cap-0.75
Enterprise Value/Revenue-2.85
Enterprise Value/Gross Profit-22.49
Enterprise Value/Ebitda0.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Committed Funding FacilityA committed $40M equity purchase facility materially extends PMGC’s funding runway and acquisition firepower for 2+ years, enabling the roll-up strategy in precision manufacturing. This reduces near-term liquidity risk and supports capex or tuck-ins without immediate revenue dependence, improving long-term execution optionality despite dilution.
Long-term Aerospace Supply DealA multi-year, mission-critical supply contract increases predictable revenue and deepens PMGC’s foothold in regulated aerospace/defense supply chains. Coupled with ITAR registration and certification progress, this creates durable customer relationships, higher switching costs, and a pathway to stable backlog and improved margin mix over subsequent reporting periods.
Exclusive Aerospace/defense IP LicenseSecuring an exclusive, worldwide license strengthens the company’s technology moat in aerospace/defense and creates a defined commercialization pathway. The structured royalties and diligence milestones align incentives with the licensor and, if developed successfully, can support recurring revenue streams and higher-margin product opportunities over multiple years.
Bears Say
Sustained Cash BurnPersistent negative OCF and FCF indicate operations do not self-fund and the company must rely on external capital to sustain growth. Over a multi-quarter horizon this elevates refinancing and dilution risk, constrains strategic investments, and forces prioritization of cash-generative integrations or financing activity over organic R&D or margin expansion.
Rising LeverageMaterial debt growth compresses financial flexibility and increases fixed obligations. Higher leverage raises default and covenant risk during continued losses, and combined with secured claims tied to financing facilities, it can limit strategic choices, increase funding costs, and pressure margins if further borrowing is needed to cover operating deficits.
Thin Margins & Deep LossesDespite strong revenue growth, profitability is materially negative with very thin gross margins, implying structural cost or pricing issues. Without sustained margin recovery or higher-margin product mix, the company cannot convert growth into positive returns, prolonging reliance on external financing and delaying potential shareholder value realization.
PMGC Holdings News
ELAB FAQ
What was PMGC Holdings’s price range in the past 12 months?
PMGC Holdings lowest stock price was $1.02 and its highest was $309.12 in the past 12 months.
What is PMGC Holdings’s market cap?
PMGC Holdings’s market cap is $4.82M.
When is PMGC Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PMGC Holdings’s earnings last quarter?
Currently, no data Available
Is PMGC Holdings overvalued?
According to Wall Street analysts PMGC Holdings’s price is currently Overvalued.
Does PMGC Holdings pay dividends?
PMGC Holdings does not currently pay dividends.
What is PMGC Holdings’s EPS estimate?
PMGC Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PMGC Holdings have?
PMGC Holdings has 4,543,751 shares outstanding.
What happened to PMGC Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PMGC Holdings?
Currently, no hedge funds are holding shares in ELAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PMGC Holdings
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
CNS Pharmaceuticals
―
Ownership Overview
73.43%
Insiders
― Other Institutional Investors
26.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---